Entries from India Chemicals Blog tagged with 'Jubilant Organosys'
More changes at Jubilant?
Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in...
Pharma still keen on M&As
The Indian pharmaceutical sector is keeping the M&A fire burning with six deals concluded last month, up from eight in the January-March period. The list includes Jubilant Organosys' $255m acquisition of US-based DRAXIS Health and the $218m buyout of Dabur...
Testing times for CRAMS
Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country's strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m,...
CRAMS: still going strong
Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals...
Jubilant CRAMS another acquisition
Jubilant Organosys $123m acquisition of US-based Hollister-Stier Labs further consolidates is position in the global custom research and manufacturing (CRAMs) business. Interestingly, Jubilant will not be moving projects to India following the acquisition. In an interview with CNBC, Hari Bhartia,...
Indian chemicals score on CRAMS
Jubiliant Organosys' announcement that it has clinched deals worth $60m from global life science majors reinforces India's growing strength in the custom research and manufacturing services (CRAMS) business. Rising competition and research costs are supporting the CRAMS outsourcing wave and...
Feed Subscription
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'Jubilant Organosys'. [What is this?]
